Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luramist
- Development stage
- Discontinued
- Lead developer
- VIVUS LLC
- Modality
- Small Molecules
- Administration
- Topical, Transdermal
01
Overview
Luramist is an investigational metered-dose transdermal spray (MDTS) formulation of testosterone. It was developed by VIVUS, Inc., under license from Acrux, specifically for the treatment of hypoactive sexual desire disorder (HSDD) in women. The product utilized a proprietary delivery system designed to provide a low dose of testosterone systemically through the skin. Clinical development reached Phase 2, but VIVUS ultimately ceased development of the program to focus resources on other products in its portfolio, such as the obesity medication Qsymia.
- Brand names
- Luramist
- Other names
- testosterone transdermal spraytestosterone MDTS
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on Luramist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luramist.